Dr Reddy's Laboratories

Dr Reddy's Q4 PAT crashes 86% on generic Revlimid shock in US market

The fall was driven by weak US sales of Revlimid, offset only partially by growth in India, Europe, and emerging markets

Dr Reddy's Q4 results: PAT down 86% at ₹221 crore, revenue drops 11.51%

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday reported an 86 per cent dip in consolidated profit after tax at Rs 221.3 crore in the fourth quarter ended March 31, 2026 hit by lower generics sales in North America. The company had posted a profit after tax of Rs 1,586.7 crore in the corresponding quarter previous fiscal year, Dr Reddy's Laboratories Ltd said in a regulatory filing. Consolidated total revenue from operations in the fourth quarter stood at Rs 7,546.4 crore as against Rs 8,528.4 crore in the same period a year ago, it added. Revenue from generic drugs in North America in the quarter was down 51 per cent at Rs 1,756.2 crore as compared to Rs 3,558.6 crore in the year-ago period. On the other hand generics revenue in India grew 20 per cent at Rs 1,566.3 crore as compared to Rs 1,304.7 crore in the corresponding period a year ago, the company said. Similarly, generics revenue in Europe grew by 14 per cent to Rs 1,452 crore from Rs 1,275 crore in the year ago period.

Q4 results: Dr Reddy's, Tata Power, Pfizer, Kalpataru among 104 on May 12

Q4FY26 company results: Firms including Berger Paints, Torrent Power, Max Financial Services, Nazara Technologies, and Vinati Organics are also to release their January-March earnings today

Dr Reddy's Q4 preview: Lower US sales to drag earnings; profit may dip 34%

Dr Reddy's net profit is expected to come at ₹1,035 crore, marking a moderate 34 per cent Y-o-Y decrease, on average, as against ₹1,587 crore in the Q4FY25

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Dr Reddy's enters semaglutide market, launches diabetes generic drug

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Analyst suggests Nifty strategy; bets on Oil India, Dr Reddy's Labs

Ajit Mishra of Religare Broking recommends Nifty strategy and two stocks to buy; check details here

Dr Reddy's likely to launch generic semaglutide Obeda in India in March

Hyderabad-based Dr Reddy's has applied to trademark the Obeda brand and logo, a government filing showed

Dr Reddy's enters hormone replacement therapy segment with $32 mn buy

Dr Reddy's Laboratories has forayed into hormone replacement therapy segment by acquiring trademarks of specialty brands, Progynova and Cyclo-Progynova and related assets, for India from UK-headquartered Mercury Pharma Group for USD 32.15 million, according to a company statement. Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components. As per IQVIA MAT December 2025, the brand recorded sales of Rs 100 crore. The acquisition strengthens Dr Reddy's gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment, the drug firm stated. "The acquisition will serve as the spearhead of our expansion into the HRT segment, ...

Stocks to Watch today, Feb 19: Dr Reddy's Labs, HUL, Cochin Shipyard, DLF

Stocks to Watch today, February 19, 2025: Dr Reddy's Labs, Hindustan Unilever, NCC, DLF, and Jindal Saw are some of the key stocks to watch today

Dr Reddy's Laboratories gains 5% on posting Q3 results; brokerages divided

In Q3, Dr Reddy's Laboratories reported a 14 per cent year-on-year (Y-o-Y) decline in consolidated net profit to ₹1,210 crore, as compared to ₹1,413 crore a year ago

Stocks to Watch today, Jan 16: RIL, Infosys, ICICI Pru AMC, Jio Financial

Stocks to watch on January 16, 2026: Stocks like Infosys, ICICI Prudential AMC, Biocon, Angel One and HDB Financial Services will remain in focus today

Dr Reddy's signs licensing pact with Immutep to develop, market cancer drug

According to the agreement, Immutep will receive from Dr Reddy's an upfront payment of $20 million (around AUD 30.2 million)

Dr Reddy's signs licensing pact to sell Australian Immutep's cancer drug

Over the last few years, Dr Reddy's has diversified its portfolio beyond generics to include cancer therapies as it battles pricing pressures in North America, its largest market

Nifty50 to hit 29,300 by end-2026? Nomura lists top 20 stock picks

Nomura expects Indian markets to trade in the range of 20-22x one-year forward earnings, assuming risk premia remain low.

Why did Dr Reddy's share rise over 2% in overall subdued market? Details

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.

Stocks to Watch today, Nov 25: Siemens Energy, Dr Reddy's, Cello, HUDCO

Stocks to Watch Today, November 25, 2025: Dr. Reddy's Labs, Siemens Energy, HUDCO, Sunteck Realty and other stocks will remain in focus; here's why

Canada notice may delay Dr Reddy's semaglutide generic launch

Health Canada's non-compliance notice may delay DRL's semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday